Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Optimal systemic treatment and real-world clinical application of ctDNA in patients with metastatic HER2-mutant lung cancer

European Journal of Cancer(2024)10.1016/j.ejca.2024.114257Source: DataRank Database

Optimal systemic treatment and real-world clinical application of ctDNA in patients with metastatic HER2-mutant lung cancer is a research paper published in European Journal of Cancer (2024). On theSindex it has a DataRank of 0. It has been cited 5 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access5 citations

Download PDF

Cite:

Linked data & code

nct

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (4 grants)Impact (FWCI 0.91)OA: greenTopics (33)IDs (PubMed, PMC, OpenAlex)Annotations (1)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (33)

Tatiana Erazo ORCID,Justin Jee ORCID,Andrea Arfè ORCID,Avantika Gupta ORCID,Luke Pike ORCID

Live enrichment

PubMed:39151324 PMC:PMC12327952 OpenAlex:https://openalex.org/W4401591672

NCI NIH HHS

Grant: R01 CA249666

NCI NIH HHS

Grant: P30 CA008748

National Cancer Institute

National Institutes of Health

FWCI

0.91

Citation Percentile

0.7%

Influential Citations

Citation Trend

2024

2025

2026

greenLicense: https://doi.org/10.15223/policy-004

repositoryhttps://pmc.ncbi.nlm.nih.gov/articles/PMC12327952/pdf/nihms-2098236.pdf

publisherhttps://api.elsevier.com/content/article/PII:S0959804924009134?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S0959804924009134?httpAccept=text/plain

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/12327952

Fields of Study

Cancer Genomics and DiagnosticsLung Cancer Treatments and MutationsLung Cancer Research StudiesMedicine

MeSH Terms

Circulating Tumor DNAAdultAgedAged, 80 and overCarcinoma, Non-Small-Cell LungFemaleHumansLung NeoplasmsMaleMiddle AgedMutationRetrospective StudiesBiomarkers, TumorReceptor, ErbB-2Erb-b2 Receptor Tyrosine Kinases

Keywords

Lung cancerMedicineOncologyMutantInternal medicineCancer researchBiologyGeneGeneticsImmunotherapyctDNANSCLCTargeted TherapyHer2 Mutation

Sustainable Development Goals

SDG 0: Good health and well-being

Optimal systemic treatment and real-world clinical application of ctDNA in patients with metastatic HER2-mutant lung cancer

FAIR Checklist

Authors (33)

Funding (4 grants)

Impact

Open Access

Topics

Annotations (Europe PMC)